0001225208-11-011387.txt : 20110406 0001225208-11-011387.hdr.sgml : 20110406 20110406140338 ACCESSION NUMBER: 0001225208-11-011387 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110404 FILED AS OF DATE: 20110406 DATE AS OF CHANGE: 20110406 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENZYME CORP CENTRAL INDEX KEY: 0000732485 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061047163 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6172527500 MAIL ADDRESS: STREET 1: 500 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: COONEY CHARLES L CENTRAL INDEX KEY: 0001021048 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14680 FILM NUMBER: 11742780 MAIL ADDRESS: STREET 1: C/O POLYPORE INTERNATIONAL, INC. STREET 2: 11430 N. COMMUNITY HOUSE ROAD, SUITE 350 CITY: CHARLOTTE STATE: NC ZIP: 28277 4 1 doc4.xml X0303 4 2011-04-04 0000732485 GENZYME CORP GENZ 0001021048 COONEY CHARLES L 500 KENDALL STREET CAMBRIDGE MA 02142 1 Genzyme common stock (GENZ) 2011-04-04 4 M 0 3827.3890 0 A 13116.3890 D Genzyme common stock (GENZ) 2011-04-04 4 M 0 2375.0000 0.0000 A 15491.3890 D Genzyme common stock (GENZ) 2011-04-04 4 M 0 149.8170 0 A 15641.2060 D Genzyme common stock (GENZ) 2011-04-04 4 D 0 2375.0000 74.0000 D 13266.2060 D Genzyme common stock (GENZ) 2011-04-04 4 D 0 3977.2060 76.0100 D 9289.0000 D Genzyme common stock (GENZ) 2011-04-04 4 U 0 8387.0000 74.0000 D 902.0000 D Genzyme common stock (GENZ) 2011-04-04 4 U 0 600.0000 74.0000 D 0.0000 I By Custodian for Grandchildren Genzyme common stock (GENZ) 2011-04-04 4 U 0 1882.0000 74.0000 D 0.0000 I By Son Genzyme common stock (GENZ) 2011-04-04 4 U 0 240.0000 74.0000 D 0.0000 I By Spouse Phantom Stock 2011-04-04 4 M 0 3827.3890 0.0000 D 2002-06-30 2026-12-31 Genzyme common stock (GENZ) 3827.3890 0.0000 D Phantom Stock 2011-04-04 4 M 0 149.8170 0.0000 D 2002-09-30 2026-12-31 Genzyme common stock (GENZ) 149.8170 0.0000 D Restricted Stock Units 0.0000 2011-04-04 4 M 0 2375.0000 0.0000 D Genzyme common stock (GENZ) 2375.0000 0.0000 D Stock Option (right to buy) 51.5200 2011-04-04 4 D 0 7125.0000 51.5200 D 2020-06-16 Genzyme common stock (GENZ) 7125.0000 0.0000 D Stock Option (right to buy) 58.6600 2011-04-04 4 D 0 7500.0000 58.6600 D 2010-05-21 2019-05-21 Genzyme common stock (GENZ) 7500.0000 0.0000 D Stock Option (right to buy) 68.4800 2011-04-04 4 D 0 7500.0000 68.4800 D 2009-05-22 2018-05-22 Genzyme common stock (GENZ) 7500.0000 0.0000 D Stock Option (right to buy) 62.1600 2011-04-04 4 D 0 15000.0000 62.1600 D 2008-05-24 2017-05-24 Genzyme common stock (GENZ) 15000.0000 0.0000 D Stock Option (right to buy) 58.5000 2011-04-04 4 D 0 15000.0000 58.5000 D 2007-05-25 2016-05-26 Genzyme common stock (GENZ) 15000.0000 0.0000 D Stock Option (right to buy) 62.9800 2011-04-04 4 D 0 15000.0000 62.9800 D 2006-05-26 2015-05-26 Genzyme common stock (GENZ) 15000.0000 0.0000 D Stock Option (right to buy) 41.5100 2011-04-04 4 D 0 1010.0000 41.5100 D 2003-05-30 2012-05-30 Genzyme common stock (GENZ) 1010.0000 0.0000 D Stock Option (right to buy) 53.4700 2011-04-04 4 D 0 2000.0000 53.4700 D 2002-05-31 2011-05-31 Genzyme common stock (GENZ) 2000.0000 0.0000 D The phantom stock acquired under the Genzyme Directors? Deferred Compensation Plan was cancelled at the completion of the sanofi-aventis tender offer and converted into the right to receive a cash payment based on the closing price of Genzyme common stock on the last day it traded. Phantom stock was credited to the Reporting Person?s stock account under the deferred compensation at the end of each fiscal quarter from 4/1/2002 through 9/30/2002, pursuant to the Reporting Person?s plan election and the terms of the plan. The vested restricted stock units were scheduled to vest on the date of the 2011 annual meeting of shareholders. This option, which provided for vesting at the next annual meeting of shareholders, was cancelled upon the consummation of the sanofi-aventis tender offer in exchange for a payment representing (A) an amount of cash equal to the excess of $74.00 over the exercise price of the option, multiplied by the total number of shares subject to such options, and (B) one contingent value right (CVR) per cancelled option. Susan P. Cogswell, Attorney-in-Fact 2011-04-06